Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (7698)	5/18/1999 6:30:00 AM
From: Anthony Wong	Respond to of 9523

Dissecting Biotech Industry's Bleak Prospects 5,000 gathering to ponder their woes at Seattle convention sfgate.com Excerpts: Meanwhile, cash-starved firms are striking Faustian bargains with large pharmaceutical companies. Big drug firms have pockets deep enough to fund biotech experiments. But if the biotech firm strikes gold with a hit drug, its Big Pharma backer will lay claim to most of the profits. Even so, local biotech firms are fortunate that Big Pharma has filled the funding gap caused by Wall Street squeamishness. Edwards, at Recombinant Capital, says Pfizer is indicative of this trend. Flush with profits from Viagra, the New York drugmaker recently opened a Bay Area office to plow at least $150 million a year back into deals with Bay Area biotech firms, he said.